Farnesoid X receptor agonists: What they are and how they might be used in treating liver disease

Current Gastroenterology Reports

Volumn 14, Issue 1, 2012, Pages 55-62

  Neuschwander Tetri, Brent A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acids; Bile salts; FGF 15; FGF 19; Fibroblast growth factor 15; Fibroblast growth factor 19; FXR, Nonalcoholic steatohepatitis; Insulin resistance; NAFLD; NASH; Nonalcoholic fatty liver disease; Nuclear receptors; Obeticholic acid; Small heterodimeric partner

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BILE ACID; BINDING PROTEIN; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR STIMULATING AGENT; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HORMONE RECEPTOR STIMULATING AGENT; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; OBETICHOLIC ACID; ORGANIC ANION TRANSPORTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; SIRTUIN 1; SMALL HETERODIMERIC PARTNER 1 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE SECRETION; CELL DEATH; CHOLELITHIASIS; CHOLESTASIS; CHOLESTEROL METABOLISM; CONFORMATIONAL TRANSITION; CONSTIPATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER CELL; LIVER DISEASE; LIVER FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PRURITUS;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; LIVER DISEASES; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84857625816     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-011-0232-6     Document Type: Article

References (56)

1. CD Williams J Stengel MI Asike, et al. 2011 Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study Gastroenterology 140 124 131 20858492 10.1053/j.gastro.2010.09.038
2. M Arrese SJ Karpen 2010 Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases Clin Pharmacol Ther 87 473 478 20200515 10.1038/clpt.2010.2 1:STN:280:DC%2BC3c7pvVSgsQ%3D%3D
3. • Wagner M, Zollner G, Trauner M: Nuclear receptors in liver disease. Hepatology 2011, 53:1023-34. An excellent update on the role of nuclear receptors in the liver.
4. •• Modica S, Gadaleta RM, Moschetta A: Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010, 8:e005. Thorough and insightful review of FXR.
5. AM Thomas SN Hart B Kong, et al. 2010 Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine Hepatology 51 1410 1419 20091679 10.1002/hep.23450 1:CAS:528:DC%2BC3cXls1Cnurg%3D
6. HK Chong AM Infante Y-K Seo, et al. 2010 Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1 Nucleic Acids Res 38 6007 6017 20483916 10.1093/nar/gkq397 1:CAS:528:DC%2BC3cXhtlSmsr7I
7. • Cariou B: The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab 2008, 34:685-691. Good review of the rationale for exploring the use of FXR ligands as a treatment for NASH.
8. IR Popescu A Helleboid-Chapman A Lucas, et al. 2010 The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity FEBS Lett 584 2845 2851 20447400 10.1016/j.febslet.2010.04.068 1:CAS:528:DC%2BC3cXntlaksbk%3D
9. S Fiorucci F Baldelli 2009 Farnesoid X receptor agonists in biliary tract disease Curr Opin Gastroenterol 25 252 259 19300246 10.1097/MOG. 0b013e328324f87e 1:CAS:528:DC%2BD1MXkvVGlsrg%3D
10. K Allen H Jaeschke BL Copple 2011 Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis Am J Pathol 178 175 186 21224055 10.1016/j.ajpath.2010.11.026 1:CAS:528:DC%2BC3MXitFGjs70%3D
11. CJ Sinal M Tohkin M Miyata, et al. 2000 Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis Cell 102 731 744 11030617 10.1016/S0092-8674(00)00062-3 1:CAS:528:DC%2BD3cXmvFShtr8%3D
12. JR Swann EJ Want FM Geier, et al. 2011 Systemic gut microbial modulation of bile acid metabolism in host tissue compartments Proc Natl Acad Sci USA 108 Suppl 1 4523 4530 20837534 10.1073/pnas.1006734107 1:CAS:528: DC%2BC3MXjvVCktb4%3D
13. R Kaimal X Song B Yan, et al. 2009 Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones J Pharmacol Exp Ther 330 125 134 19369578 10.1124/jpet.109.151233 1:CAS:528:DC%2BD1MXosFeltLs%3D
14. S Bhatnagar HA Damron FB Hillgartner 2009 Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis J Biol Chem 284 10023 10033 19233843 10.1074/jbc.M808818200 1:CAS:528:DC%2BD1MXjvFKlu7k%3D
15. X Wu H Ge B Lemon, et al. 2009 Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice Proc Natl Acad Sci USA 106 14379 14384 19706524 10.1073/pnas.0907812106 1:CAS:528:DC%2BD1MXhtFaiu73M
16. I Kim SH Ahn T Inagaki, et al. 2007 Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine J Lipid Res 48 2664 2672 17720959 10.1194/jlr.M700330-JLR200 1:CAS:528:DC%2BD2sXhsValtLzM (Pubitemid 350272851)
17. S Anakk M Watanabe SA Ochsner, et al. 2011 Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis J Clin Invest 121 86 95 21123943 10.1172/JCI42846 1:CAS:528:DC%2BC3MXis1ynsw%3D%3D
18. L Fu LM John SH Adams, et al. 2004 Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes Endocrinology 145 2594 2603 14976145 10.1210/en.2003-1671 1:CAS:528:DC%2BD2cXkt12gt7s%3D (Pubitemid 38686202)
19. AM Strack RW Myers 2004 Modulation of metabolic syndrome by fibroblast growth factor 19 (FGF19)? Endocrinology 145 2591 2593 15140837 10.1210/en.2004-0367 1:CAS:528:DC%2BD2cXkt12gt7o%3D (Pubitemid 38686201)
20. HB Hartman K Lai MJ Evans 2009 Loss of small heterodimer partner expression in the liver protects against dyslipidemia J Lipid Res 50 193 203 18820241 10.1194/jlr.M800323-JLR200 1:CAS:528:DC%2BD1MXhsVCmsLc%3D
21. • Kemper JK, Xiao Z, Ponugoti B, et al.: FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009, 10:392-404. Important paper examining what may be an underappreciated role of acetylation in modulating FXR function.
22. S Fiorucci G Rizzo A Donini, et al. 2007 Targeting farnesoid X receptor for liver and metabolic disorders Trends Mol Med 13 298 309 17588816 10.1016/j.molmed.2007.06.001 1:CAS:528:DC%2BD2sXnsFKku78%3D (Pubitemid 47017005)
23. •• Lee J, Padhye A, Sharma A, et al.: A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem 2010, 285:12604-12611. Regulation of micro-RNA species may be an important new area for understanding how FXR regulates gene expression.
24. S Sookoian CJ Pirola 2011 Metabolic syndrome: from the genetics to the pathophysiology Curr Hypertens Rep 13 149 157 20957457 10.1007/s11906-010-0164-9 1:CAS:528:DC%2BC3MXisFyhtL4%3D
25. AJ Sanyal S Mudaliar RR Henry, et al. 2009 A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the first FXR hepatic therapeutic study (abstract) Hepatology 50 389A 390A
26. T Claudel B Staels F Kuipers 2005 The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism Arterioscler Thromb Vasc Biol 25 2020 2030 16037564 10.1161/01.ATV.0000178994.21828.a7 1:CAS:528:DC%2BD2MXhtVCltrjM (Pubitemid 41416297)
27. F Kuipers JH Stroeve S Caron B Staels 2007 Bile acids, farnesoid X receptor, atherosclerosis and metabolic control Curr Opin Lipidol 18 289 297 17495603 10.1097/MOL.0b013e3281338d08 1:CAS:528:DC%2BD2sXltFSks70%3D (Pubitemid 46743053)
28. YD Wang WD Chen M Wang, et al. 2008 Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response Hepatology 48 1632 1643 18972444 10.1002/hep.22519 1:CAS:528:DC%2BD1cXhsVKmt77J
29. DA Blasiole RA Davis AD Attie 2007 The physiological and molecular regulation of lipoprotein assembly and secretion Mol Biosyst 3 608 619 17700861 10.1039/b700706j 1:CAS:528:DC%2BD2sXptVWiurc%3D (Pubitemid 47258227)
30. A Thomas 2010 Genome-wide tissue-specific farnisoid X receptor binding in mouse liver and intestine Hepatology 51 1410 1419 20091679 10.1002/hep.23450 1:CAS:528:DC%2BC3cXls1Cnurg%3D
31. B Cariou K van Harmelen D Duran-Sandoval, et al. 2006 The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice J Biol Chem 281 11039 11049 16446356 10.1074/jbc.M510258200 1:CAS:528: DC%2BD28XjsFWjs7w%3D (Pubitemid 43855527)
32. K Ma PK Saha L Chan DD Moore 2006 Farnesoid X receptor is essential for normal glucose homeostasis J Clin Invest 116 1102 1109 16557297 10.1172/JCI25604 1:CAS:528:DC%2BD28XjsVWnurk%3D
33. D Duran-Sandoval B Cariou J-C Fruchart B Staels 2005 Potential regulatory role of the farnesoid X receptor in the metabolic syndrome Biochimie 87 93 98 15733743 10.1016/j.biochi.2004.11.018 1:CAS:528:DC%2BD2MXhslCntLg%3D (Pubitemid 40298771)
34. • Anderson N, Borlak J: Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008, 60:311-357. Extensive review of the mechanisms of hepatic steatosis and non-triglyceride lipotoxicity as well as the intracellular processes leading to lipid droplet accumulation.
35. NM Bass 2010 Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffic Hepatology 51 4 7 20034031 10.1002/hep.23458 1:CAS:528:DC%2BC3cXhsVCqtL8%3D
36. BA Neuschwander-Tetri 2010 Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites Hepatology 52 774 788 20683968 10.1002/hep.23719
37. Y Zhang FY Lee G Barrera, et al. 2006 Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice Proc Natl Acad Sci USA 103 1006 1011 16410358 10.1073/pnas.0506982103 1:CAS:528: DC%2BD28XhsVKgtLY%3D (Pubitemid 43212212)
38. G Rizzo M Disante A Mencarelli, et al. 2006 The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo Mol Pharmacol 70 1164 1173 16778009 10.1124/mol.106.023820 1:CAS:528: DC%2BD28XhtVOjt7nE (Pubitemid 44435967)
39. S Fiorucci G Rizzo E Antonelli, et al. 2005 Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis J Pharmacol Exp Ther 315 58 68 15980055 10.1124/jpet.105.085597 1:CAS:528:DC%2BD2MXhtVOksrfJ (Pubitemid 41380498)
40. ML Crawley 2010 Farnesoid X receptor modulators: a patent review Expert Opin 20 1047 1057 10.1517/13543776.2010.496777 1:CAS:528:DC%2BC3cXpt1SltLY%3D
41. M Trauner T Claudel P Fickert, et al. 2010 Bile acids as regulators of hepatic lipid and glucose metabolism Dig Dis 28 220 224 20460915 10.1159/000282091
42. S Cipriani A Mencarelli G Palladino S Fiorucci 2010 FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats J Lipid Res 51 771 784 19783811 10.1194/jlr.M001602 1:CAS:528:DC%2BC3cXjslenurs%3D
43. B Kong JP Luyendyk O Tawfik GL Guo 2009 Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet J Pharmacol Exp Ther 328 116 122 18948497 10.1124/jpet.108.144600 1:CAS:528:DC%2BD1MXisFylsQ%3D%3D
44. M Watanabe SM Houten L Wang, et al. 2004 Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c J Clin Invest 113 1408 1418 15146238 1:CAS:528:DC%2BD2cXktlCltro%3D (Pubitemid 39071696)
45. JK Reddy T Hashimoto 2001 Peroxisomal β-oxidation and peroxisome proliferator-activated receptor α: an adaptive metabolic system Annu Rev Nutr 21 193 230 11375435 10.1146/annurev.nutr.21.1.193 1:CAS:528: DC%2BD3MXlvFyku78%3D (Pubitemid 32695270)
46. I Pineda Torra T Claudel C Duval, et al. 2003 Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor Mol Endocrinol 17 259 272 12554753 10.1210/me.2002-0120 (Pubitemid 36183149)
47. TCMA Schreuder HA Marsman M Lenicek, et al. 2010 The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance Am J Physiol Gastrointest Liver Physiol 298 G440 445 20093562 10.1152/ajpgi.00322.2009 1:CAS:528:DC%2BC3cXjsFGgt7c%3D
48. NY Kalaany DJ Mangelsdorf 2006 LXRs and FXR: the yin and yang of cholesterol and fat metabolism Annu Rev Physiol 68 159 191 16460270 10.1146/annurev.physiol.68.033104.152158 1:CAS:528:DC%2BD28XksFWksrs%3D
49. Kowdley KV, Jones D, Luketic VA, et al.: An international study evaluating the farnesoid x receptor agonist obeticholic acid as monotherapy in PBC. J Hepatol 2011, 54 Suppl 1:S13.
50. YD Wang F Yang WD Chen, et al. 2008 Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo Mol Endocrinol 22 1622 1632 18436567 10.1210/me.2007-0527 1:CAS:528: DC%2BD1cXot1ehurs%3D (Pubitemid 351920395)
51. S Fiorucci G Rizzo E Antonelli, et al. 2005 A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis J Pharmacol Exp Ther 314 584 595 15860571 10.1124/jpet.105.084905 1:CAS:528:DC%2BD2MXntVSisr0%3D (Pubitemid 41043838)
52. FY Lee HR Kast-Woelbern J Chang, et al. 2005 Alpha-crystallin is a target gene of the farnesoid X-activated receptor in human livers J Biol Chem 280 31792 31800 16012168 10.1074/jbc.M503182200 1:CAS:528:DC%2BD2MXpslejsLg%3D (Pubitemid 41291929)
53. P Fickert A Fuchsbichler T Moustafa, et al. 2009 Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts Am J Pathol 175 2392 2405 19910507 10.2353/ajpath.2009.090114 1:CAS:528: DC%2BC3cXkt12msg%3D%3D
54. M Watanabe SM Houten C Mataki, et al. 2006 Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 439 484 489 16400329 10.1038/nature04330 1:CAS:528:DC%2BD28XntFWmuw%3D%3D (Pubitemid 43152840)
55. JD Baxter P Webb 2006 Metabolism: bile acids heat things up Nature 439 402 403 16437098 10.1038/439402a 1:CAS:528:DC%2BD28XntFWnsQ%3D%3D (Pubitemid 43152820)
56. AJ Wigg IC Roberts-Thomson RB Dymock, et al. 2001 The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis Gut 48 206 211 11156641 10.1136/gut.48.2.206 1:STN:280:DC%2BD3M7is1Wgtw%3D%3D (Pubitemid 32141844)